Savara at a Glance
Savara Pharmaceuticals is a U.S.-based emerging pharmaceutical development company with an affiliate site in Denmark. The company is focused on advancing a pipeline of novel inhalation therapies for the treatment of patients with rare pulmonary conditions.
- Molgradex – Inhaled nebulized GM-CSF to treat Pulmonary Alveolar Proteinosis (PAP)
- AeroVanc – Inhaled dry-powder Vancomycin to treat chronic methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection in Cystic Fibrosis (CF)
- Aironite – an inhaled sodium nitrite solution to treat heart failure with preserved ejection fraction (HFpEF)
Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor) is the first inhaled product being developed for the treatment of patients with PAP. PAP is a rare lung disease characterized by the build-up of lung surfactant in the alveoli, or air sacs, of the lungs. The disease process underlying PAP involves an autoimmune response against a naturally occurring protein, GM-CSF, suppressing the stimulating activity of GM-CSF on lung macrophages which function to clear excess surfactant from the alveoli. Based on published investigator-sponsored treatment experience with inhaled GM-CSF, Savara believes Molgradex has the potential to replace the inactivated GM-CSF in PAP patients, and thereby to restore the surfactant clearing activity of the alveolar macrophages.
AeroVanc (vancomycin hydrochloride inhalation powder), is an inhaled dry powder form of vancomycin to treat Methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis patients. By delivering vancomycin directly to the site of infection in the lungs, the hope is that AeroVanc will improve clinical efficacy and reduce adverse effects due to lessor systemic drug exposure as compared to IV antibiotic treatment. AeroVanc is the first inhaled antibiotic for management of MRSA lung infection in CF patients.
Aironite (sodium nitrite solution), is inhaled via nebulizer to treat heart failure patients with preserved ejection fraction (HFpEF). Data show that approximately 50% of patients hospitalized for heart failure have HFpEF and the prevalence of HFpEF is expected to increase as the population ages. By delivering inorganic nitrite directly to the lungs, the hope is Aironite will correct abnormalities that occur following heart failure that can limit exercise capacity.